$ACET
Adicet Bio, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021004111 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q2
Revenue $5.468M $3.429M $4.814M
YoY Change 1.07% 13.17% -49.17%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.352M $5.213M $5.025M
YoY Change 25.04% -32.65% -32.09%
% of Gross Profit
Research & Development $13.46M $11.93M $10.62M
YoY Change 39.03% 33.37% 22.36%
% of Gross Profit
Depreciation & Amortization $365.0K $388.0K $455.0K
YoY Change 14.06% -53.81% 1037.5%
% of Gross Profit
Operating Expenses $19.81M $17.14M $15.64M
YoY Change 34.21% 2.73% -2.82%
Operating Profit -$13.71M -$10.83M
YoY Change 0.4% 25.46%
Interest Expense $12.00K $50.00K $51.00K
YoY Change -60.0% 0.0% 50.0%
% of Operating Profit
Other Income/Expense, Net -$294.0K -$246.0K -$62.00K
YoY Change -233.64% -79.9% 210.0%
Pretax Income -$15.82M -$14.00M -$10.93M
YoY Change 73.89% -5.24% 29.28%
Income Tax -$11.00K $11.00K -$77.00K
% Of Pretax Income
Net Earnings -$15.81M -$14.01M -$10.85M
YoY Change 76.48% -5.18% 28.37%
Net Earnings / Revenue -289.19% -408.66% -225.47%
Basic Earnings Per Share -$0.44
Diluted Earnings Per Share -$465.8K -$439.6K -$341.1K
COMMON SHARES
Basic Shares Outstanding 31.96M 31.84M
Diluted Shares Outstanding 31.88M

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $277.5M $192.2M $208.7M
YoY Change 193.34% 77.79% 194.39%
Cash & Equivalents $277.5M $192.2M $208.7M
Short-Term Investments $0.00 $0.00 $0.00
Other Short-Term Assets $31.00K $1.000K $373.0K
YoY Change -86.46% -98.18% -87.14%
Inventory
Prepaid Expenses $115.0K $655.0K $1.045M
Receivables $185.0K
Other Receivables $29.00K
Total Short-Term Assets $282.4M $199.0M $216.3M
YoY Change 181.49% 69.51% 193.3%
LONG-TERM ASSETS
Property, Plant & Equipment $14.64M $11.40M $11.40M
YoY Change 424.84% 457.76% 3174.43%
Goodwill $19.46M $19.46M $19.46M
YoY Change -3.12% -6.16%
Intangibles $0.00
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change
Other Assets $1.887M $1.921M $2.002M
YoY Change 2.72% -12.16% 901.0%
Total Long-Term Assets $56.50M $58.17M $52.48M
YoY Change 5.61% 76.33% 8749.07%
TOTAL ASSETS
Total Short-Term Assets $282.4M $199.0M $216.3M
Total Long-Term Assets $56.50M $58.17M $52.48M
Total Assets $338.9M $257.2M $268.8M
YoY Change 120.33% 71.01% 261.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.263M $4.631M $2.316M
YoY Change 110.24% 21.87% -6.12%
Accrued Expenses $8.249M $5.313M $5.484M
YoY Change 19.55% -21.87% 399.91%
Deferred Revenue $4.805M $10.09M $13.15M
YoY Change -65.63% -47.97%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.32M $20.03M $20.95M
YoY Change -27.41% -33.4% 487.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $115.0K $116.0K $19.49M
YoY Change 182.93% 57223.53%
Total Long-Term Liabilities $115.0K $116.0K $19.49M
YoY Change 182.93% 57223.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.32M $20.03M $20.95M
Total Long-Term Liabilities $115.0K $116.0K $19.49M
Total Liabilities $35.81M $39.97M $40.44M
YoY Change -18.63% 19.43% 1023.87%
SHAREHOLDERS EQUITY
Retained Earnings -$168.3M -$152.5M -$138.5M
YoY Change 58.31% 56.64%
Common Stock $471.5M $369.7M $366.8M
YoY Change 118.14% 72.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $303.1M $217.2M $228.3M
YoY Change
Total Liabilities & Shareholders Equity $338.9M $257.2M $268.8M
YoY Change 120.33% 71.01% 261.54%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q2
OPERATING ACTIVITIES
Net Income -$15.81M -$14.01M -$10.85M
YoY Change 76.48% -5.18% 28.37%
Depreciation, Depletion And Amortization $365.0K $388.0K $455.0K
YoY Change 14.06% -53.81% 1037.5%
Cash From Operating Activities -$13.44M -$9.684M -$12.77M
YoY Change 0.78% 23.68% 139.21%
INVESTING ACTIVITIES
Capital Expenditures -$3.078M -$7.178M -$2.130M
YoY Change 755.0% 1039.37%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $1.750M
YoY Change -100.0% -100.0% -88.33%
Cash From Investing Activities -$3.078M -$7.178M -$380.0K
YoY Change -124.72% -115.86% -102.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 97.46M 362.0K -30.00K
YoY Change 37385.77% 805.0%
NET CHANGE
Cash From Operating Activities -13.44M -9.684M -12.77M
Cash From Investing Activities -3.078M -7.178M -380.0K
Cash From Financing Activities 97.46M 362.0K -30.00K
Net Change In Cash 80.94M -16.50M -13.18M
YoY Change -12947.78% -144.02% -236.48%
FREE CASH FLOW
Cash From Operating Activities -$13.44M -$9.684M -$12.77M
Capital Expenditures -$3.078M -$7.178M -$2.130M
Free Cash Flow -$10.37M -$2.506M -$10.64M
YoY Change -20.14% -65.19% 99.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Transition Report
DocumentTransitionReport
false
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
acet Issuance Of Redeemable Convertible Preferred Stock On Exercise Of Warrants With Loan Agreement
IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
acet Proceeds From Sales Of Marketable Debt Securities
ProceedsFromSalesOfMarketableDebtSecurities
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
acet Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
CY2021Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Other Noncash Expense
OtherNoncashExpense
dei Amendment Flag
AmendmentFlag
false
acet Adjustment To Goodwill
AdjustmentToGoodwill
dei Entity Central Index Key
EntityCentralIndexKey
0001720580
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
CY2021Q3 us-gaap Development In Process
DevelopmentInProcess
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-11-30
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity File Number
EntityFileNumber
001-38359
dei Entity Registrant Name
EntityRegistrantName
Adicet Bio, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3305277
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Clarendon Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Floor 6
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02116
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
503-9095
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ACET
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31955450
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192226000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84330000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
10284000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6799000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5722000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
199025000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
100336000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11395000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2790000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20865000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23066000
CY2021Q3 us-gaap Goodwill
Goodwill
19462000
CY2020Q4 us-gaap Goodwill
Goodwill
20089000
CY2020Q4 us-gaap Development In Process
DevelopmentInProcess
1190000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4527000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4527000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1921000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1837000
CY2021Q3 us-gaap Assets
Assets
257195000
CY2020Q4 us-gaap Assets
Assets
153835000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4631000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1552000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10088000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
13980000
CY2021Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4601000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5732000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
712000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1215000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
20032000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22479000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19823000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20424000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
980000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
125000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
116000
CY2021Q3 us-gaap Liabilities
Liabilities
39971000
CY2020Q4 us-gaap Liabilities
Liabilities
44008000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31955050
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31955050
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19677249
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19677249
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
369732000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
216126000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152511000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-106325000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
24000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
217224000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
109827000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
257195000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
153835000
CY2021Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
3429000
CY2020Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
3028000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
4262000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
12493000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11926000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8942000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34285000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24651000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5213000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7741000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15868000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17684000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
17139000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
16683000
us-gaap Operating Expenses
OperatingExpenses
50153000
us-gaap Operating Expenses
OperatingExpenses
42335000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13710000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13655000
us-gaap Operating Income Loss
OperatingIncomeLoss
-45891000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29842000
CY2021Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
4000
CY2020Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
153000
us-gaap Interest And Other Income
InterestAndOtherIncome
54000
us-gaap Interest And Other Income
InterestAndOtherIncome
704000
CY2021Q3 us-gaap Interest Expense
InterestExpense
50000
CY2020Q3 us-gaap Interest Expense
InterestExpense
50000
us-gaap Interest Expense
InterestExpense
151000
us-gaap Interest Expense
InterestExpense
84000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-246000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1224000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-312000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1174000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14002000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14776000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46300000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30396000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-114000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2676000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14013000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-14779000
us-gaap Net Income Loss
NetIncomeLoss
-46186000
us-gaap Net Income Loss
NetIncomeLoss
-27720000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.84
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.54
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.69
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31876016
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5208887
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29954616
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3190557
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-114000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
60000
CY2021Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
0
CY2020Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-114000
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-24000
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
60000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14013000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14893000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46210000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27660000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
109827000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
976000
CY2021Q1 acet Stock Issued During Period Value Related To Financing
StockIssuedDuringPeriodValueRelatedToFinancing
143754000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3043000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-21319000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-22
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
236259000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
279000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2659000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10854000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
228341000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
367000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2529000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14013000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
217224000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-60366000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4486000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
42000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
299000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-15000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-64526000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8455000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
351000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
189000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-72434000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-14779000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
144000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2966000
CY2020Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
114083000
CY2020Q3 acet Stock Exchanged During Period Value In Connection With Merger
StockExchangedDuringPeriodValueInConnectionWithMerger
84142000
CY2020Q3 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2922000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-114000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
116930000
us-gaap Profit Loss
ProfitLoss
-46186000
us-gaap Profit Loss
ProfitLoss
-27720000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1173000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
911000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-190000
us-gaap Other Noncash Expense
OtherNoncashExpense
2201000
us-gaap Share Based Compensation
ShareBasedCompensation
8231000
us-gaap Share Based Compensation
ShareBasedCompensation
3616000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-10000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
897000
acet Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
151000
acet Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
84000
acet Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
1190000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-980000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
462000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5000000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
81000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1560000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3079000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1442000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3892000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2493000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-119000
acet Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1104000
acet Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
0
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1244000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1738000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
116000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37608000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28207000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
64114000
acet Proceeds From Sales Of Marketable Debt Securities
ProceedsFromSalesOfMarketableDebtSecurities
7500000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5700000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
2750000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
44985000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9968000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
630000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
282000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
102769000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
143754000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1622000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
193000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
154000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
157000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
145222000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
107896000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
74598000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88857000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14889000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
196753000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89487000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192226000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84960000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4527000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4527000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
196753000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89487000
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
214000
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
3000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2585000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
76000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
144083000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2922000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
84142000
acet Issuance Of Redeemable Convertible Preferred Stock On Exercise Of Warrants With Loan Agreement
IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement
144000
acet Adjustment To Goodwill
AdjustmentToGoodwill
413000
acet Entity Date Of Merger
EntityDateOfMerger
2020-04-28
CY2021Q3 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.25
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-7
CY2020Q3 acet Exchange Ratio1
ExchangeRatio1
0.1240
CY2021Q3 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.25
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, and marketable debt securities. The Company’s cash and cash equivalents are held at two financial institutions in the U.S. and one financial institution in Israel and such amounts may, at times, exceed insured limits. The Company invests its cash equivalents and marketable debt securities in money market funds, U.S. government securities, commercial paper, corporate bonds, and asset-backed securities. The Company limits its credit risk associated with cash equivalents and marketable debt securities by placing them with banks and institutions it believes are highly creditworthy and in highly rated investments. The Company has not experienced any losses on its deposits of cash and cash equivalents and marketable debt securities to date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> customer, Regeneron, which represents </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company’s total revenue for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three and nine months ended September 30, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 2020 (see Note 10).</span></p>
CY2021Q3 acet Number Of Customer
NumberOfCustomer
1
CY2020Q3 acet Number Of Customer
NumberOfCustomer
1
acet Customers Percentage Of Total Revenue
CustomersPercentageOfTotalRevenue
1
acet Customers Percentage Of Total Revenue
CustomersPercentageOfTotalRevenue
1
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-7
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P60D
CY2020 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
2300000
CY2021Q1 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
500000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
700000
CY2021Q3 acet Estimated Fair Value Of Cvr Liability
EstimatedFairValueOfCVRLiability
0
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
10260000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
24000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
10284000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
10284000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2021Q3 us-gaap Marketable Securities
MarketableSecurities
0
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
10284000
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
655000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
761000
CY2021Q3 acet Prepayments To Cros
PrepaymentsToCros
1643000
CY2020Q4 acet Prepayments To Cros
PrepaymentsToCros
420000
CY2021Q3 acet Prepayments To Cmos
PrepaymentsToCmos
1340000
CY2020Q4 acet Prepayments To Cmos
PrepaymentsToCmos
135000
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
449000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1443000
CY2021Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2711000
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2711000
CY2021Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
0
CY2020Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
23000
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
229000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6799000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5722000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17358000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7654000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5963000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4864000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11395000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2790000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
CY2021Q3 acet Increase In Construction In Progress
IncreaseInConstructionInProgress
6800000
acet Increase In Construction In Progress
IncreaseInConstructionInProgress
9400000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3316000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3833000
CY2021Q3 acet Accrued Cro Costs
AccruedCroCosts
490000
CY2020Q4 acet Accrued Cro Costs
AccruedCroCosts
955000
CY2021Q3 acet Accrued Cmo Costs
AccruedCmoCosts
165000
CY2020Q4 acet Accrued Cmo Costs
AccruedCmoCosts
244000
CY2021Q3 acet Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
294000
CY2020Q4 acet Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
65000
CY2021Q3 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
301000
CY2020Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
363000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
35000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
272000
CY2021Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4601000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5732000
acet Exercised Investment Right And Purchased
ExercisedInvestmentRightAndPurchased
10000000.0
acet Licence Agreement Cumulative Revenue Recognised
LicenceAgreementCumulativeRevenueRecognised
35300000
acet Contract Assets
ContractAssets
0
acet Increase Decrease In Lease Obligation
IncreaseDecreaseInLeaseObligation
0
CY2021Q2 acet Amended Lease Agreement Description
AmendedLeaseAgreementDescription
the Company entered into an amendment to the Menlo Park lease to extend the term of the lease from March 31, 2022 to June 30, 2022 and replace the previously leased premises (known as 173 and 175-177 Jefferson Drive) with another nearby premises (known as 235 Constitution Drive).
acet Operating Leases Commencement Date
OperatingLeasesCommencementDate
2021-07-15
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-06-30
CY2021Q3 acet Operating Leases Future Minimum Sublease Income Remainder Of Fiscal Year
OperatingLeasesFutureMinimumSubleaseIncomeRemainderOfFiscalYear
174000
CY2021Q3 acet Operating Leases Future Minimum Sublease Income Due Current
OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent
697000
CY2021Q3 acet Operating Leases Future Minimum Sublease Income Due In Two Years
OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears
711000
CY2021Q3 acet Operating Leases Future Minimum Sublease Income Due In Three Years
OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears
725000
CY2021Q3 acet Operating Leases Future Minimum Sublease Income Due In Four Years
OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears
740000
CY2021Q3 acet Operating Leases Future Minimum Sublease Income Due After Year Four
OperatingLeasesFutureMinimumSubleaseIncomeDueAfterYearFour
439000
CY2021Q3 acet Operating Leases Future Minimum Sublease Income Due
OperatingLeasesFutureMinimumSubleaseIncomeDue
3486000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
503000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2933000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3428000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3525000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3625000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
13747000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
27761000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7226000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
20535000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
712000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19823000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2020Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
220890
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7407902
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5672757
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2529000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2966000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8231000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3616000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1739621
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3706945
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.90
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M23D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15126000
acet Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized
2287089
acet Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted
2171632
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1954472
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.89
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
546642
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.98
acet Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled
838419
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
838419
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
14.15
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2693497
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4276356
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.10
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M15D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2101000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1329752
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.77
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M29D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1907000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4276356
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
13.10
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y11M15D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2101000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.780
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.782
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.771
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.964
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.779
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.798
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.726
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.963
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.009
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.012
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.001
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.004
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.001
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.012
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.001
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.017
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
362503
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14013000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14779000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-46186000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27720000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31876016
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5208887
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29954616
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3190557
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.84
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.54
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.69
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4497246
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14117079

Files In Submission

Name View Source Status
0000950170-21-004111-index-headers.html Edgar Link pending
0000950170-21-004111-index.html Edgar Link pending
0000950170-21-004111.txt Edgar Link pending
0000950170-21-004111-xbrl.zip Edgar Link pending
acet-20210930.htm Edgar Link pending
acet-20210930.xsd Edgar Link pending
acet-20210930_cal.xml Edgar Link unprocessable
acet-20210930_def.xml Edgar Link unprocessable
acet-20210930_htm.xml Edgar Link completed
acet-20210930_lab.xml Edgar Link unprocessable
acet-20210930_pre.xml Edgar Link unprocessable
acet-ex31_1.htm Edgar Link pending
acet-ex31_2.htm Edgar Link pending
acet-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending